company background image
SFOS.F logo

Shanghai Fosun Pharmaceutical (Group) OTCPK:SFOS.F Stock Report

Last Price

US$1.78

Market Cap

US$8.5b

7D

0%

1Y

-15.2%

Updated

23 Dec, 2024

Data

Company Financials +

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

OTCPK:SFOS.F Stock Report

Market Cap: US$8.5b

SFOS.F Stock Overview

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. More details

SFOS.F fundamental analysis
Snowflake Score
Valuation0/6
Future Growth3/6
Past Performance0/6
Financial Health4/6
Dividends1/6

Rewards

Earnings are forecast to grow 29.08% per year

Risk Analysis

Shares are highly illiquid

Profit margins (5.1%) are lower than last year (8.3%)

Large one-off items impacting financial results


My Notes

Capture your thoughts, links and company narrative

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Competitors

Jazz Pharmaceuticals

NasdaqGS:JAZZ

US$7.4b

Elanco Animal Health

NYSE:ELAN

US$5.7b

Royalty Pharma

NasdaqGS:RPRX

US$14.7b

Prestige Consumer Healthcare

NYSE:PBH

US$3.9b

Price History & Performance

Summary of share price highs, lows and changes for Shanghai Fosun Pharmaceutical (Group)
Historical stock prices
Current Share PriceCN¥1.78
52 Week HighCN¥2.24
52 Week LowCN¥1.50
Beta0.72
1 Month Change-11.00%
3 Month Change18.51%
1 Year Change-15.24%
3 Year Change-60.08%
5 Year Change-41.06%
Change since IPO-47.49%

Recent News & Updates

Recent updates

Shareholder Returns

SFOS.FUS PharmaceuticalsUS Market
7D0%-0.3%-2.7%
1Y-15.2%7.9%23.4%

Return vs Industry: SFOS.F underperformed the US Pharmaceuticals industry which returned 7.9% over the past year.

Return vs Market: SFOS.F underperformed the US Market which returned 23.4% over the past year.

Price Volatility

Is SFOS.F's price volatile compared to industry and market?
SFOS.F volatility
SFOS.F Average Weekly Movementn/a
Pharmaceuticals Industry Average Movement10.6%
Market Average Movement6.3%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.2%

Stable Share Price: SFOS.F's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine SFOS.F's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
199439,309Deyong Wenwww.fosunpharma.com

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. develops, manufactures, and sells pharmaceutical products in Mainland China and internationally. The company’s product pipeline includes HLX15, a recombinant anti-CD38 human monoclonal antibody injection for treatment of multiple myeloma; HLX13, an anti-CTLA-4 human monoclonal antibody for the treatment of melanoma, renal cell carcinoma, colorectal cancer, hepatocellular carcinoma, non-small cell lung cancer, malignant pleural mesothelioma, and esophageal squamous cell cancer; SZEY-2108 for the treatment of carbapenem resistant enterobacteriaceae (CRE) infection; XH-S003 for the treatment of IgA nephropathy and other glomerular diseases; HLX43, an antibody-drug for the treatment of metastatic solid tumors; XS-03 for the treatment of RAS-mutated advanced solid tumor; OP0595, a nacubactam for the treatment of aerobic gram-negative bacteria; XH-S002 for the treatment of ischemic stroke and transient ischemic attack which are in Phase I; HLX26, anti-LAG-3 humanized monoclonal antibody injection for the treatment of metastatic colorectal cancer; FCN-338 for the treatment of myeloid malignancies; FCN-159 for the treatment of langerhans cell histiocytosis; HLX208, a BRAF V600E inhibitor for the treatment of non-small cell lung cancer which are in phase II; FS-1502, a HER2 humanized monoclonal antibody-monomethyl auristatin F injection for the treatment of HER2-positive locally advanced or metastatic breast cancer; FCN-159 for the treatment of neurofibromatosis; ET-26, a methoxyetomidate hydrochloride for the treatment of general anesthesia which are in phase III.

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Fundamentals Summary

How do Shanghai Fosun Pharmaceutical (Group)'s earnings and revenue compare to its market cap?
SFOS.F fundamental statistics
Market capUS$8.47b
Earnings (TTM)US$289.72m
Revenue (TTM)US$5.70b

32.6x

P/E Ratio

1.7x

P/S Ratio

Is SFOS.F overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
SFOS.F income statement (TTM)
RevenueCN¥41.61b
Cost of RevenueCN¥21.83b
Gross ProfitCN¥19.78b
Other ExpensesCN¥17.67b
EarningsCN¥2.11b

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)0.80
Gross Margin47.55%
Net Profit Margin5.08%
Debt/Equity Ratio55.0%

How did SFOS.F perform over the long term?

See historical performance and comparison

Dividends

1.0%

Current Dividend Yield

34%

Payout Ratio

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 05:40
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is covered by 31 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ling ZhangBNP Paribas Securities (Asia)
Wai Chak YuenBOCI Research Ltd.
Yang HuangBofA Global Research